CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

zanubrutinib

Last Updated: March 23, 2021
Result type: Reports
Project Number: PC0248-000
Product Line: Reimbursement Review

Generic Name: zanubrutinib

Brand Name: Brukinsa

Manufacturer: BeiGene, Ltd.

Therapeutic Area: Waldenström’s macroglobulinemia

Indications: For the treatment of patients with Waldenström’s macroglobulinemia (WM)

Manufacturer Requested Reimbursement Criteria1: For the treatment of patients with Waldenström’s macroglobulinemia (WM)

Submission Type: Initial

Tumour Type: Lymphoma

Project Status: Pending

Call for patient/clinician input open: March 23, 2021

Call for patient/clinician input closed: May 14, 2021

Anticipated Date: April 21, 2021

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback